Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
BackgroundAlthough positive Circulating tumor cells (CTCs) status has been validated as a prognostic marker in breast cancer, the interaction between immune cells and CTCs during the progress of Epithelial-mesenchymal-transition (EMT), and the clinical implications of CTC-associated white blood cell...
Main Authors: | Xiuwen Guan, Chunxiao Li, Yiqun Li, Jiani Wang, Zongbi Yi, Binliang Liu, Hongyan Chen, Jiasen Xu, Haili Qian, Binghe Xu, Fei Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.602222/full |
Similar Items
-
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
by: Xiuwen Guan, et al.
Published: (2019-01-01) -
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
by: Binliang Liu, et al.
Published: (2022-07-01) -
Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
by: Xiuwen Guan, et al.
Published: (2020-07-01) -
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
by: Zongbi Yi, et al.
Published: (2019-05-01) -
Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
by: Hongnan Mo, et al.
Published: (2020-10-01)